Company Overview
Xilio Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to the discovery and development of tumor-activated immuno-oncology therapies, specifically focusing on a checkpoint inhibitor program that includes the investigational agent XTX101. The firm functions within the Healthcare sector and the Biotechnology industry, a landscape characterized by high research and development costs and significant regulatory hurdles for bringing new therapies to market. As of the latest data, the company maintains a market capitalization of $587.29M, generates annual revenue of $31.80M, and employs a workforce of 64 individuals. These financial figures indicate that the company holds a mid-sized capitalization relative to large-cap pharmaceutical peers, reflecting a position where it has secured sufficient funding to advance its clinical pipeline while still requiring substantial capital to achieve commercial profitability.
Financial Health
The company reported revenue of $31.80M for the trailing twelve months, yet this generated a net income of $-58,489,000 and an EBITDA of $-42,181,000, revealing a cost structure where operating expenses significantly outpace top-line sales due to the inherent burn rate of clinical-stage development. This financial profile is further evidenced by a free cash flow of $-20,778,876, which indicates that the company is currently consuming cash reserves rather than generating liquidity from operations, a typical condition for entities in the early phases of drug development. The gross margin stands at 82.6%, suggesting that the cost of goods sold for any potential sales is low relative to revenue, while the operating margin of -10.1% and profit margin of -183.9% highlight the substantial overhead costs associated with research, development, and general administrative functions. Despite these negative margins, the balance sheet demonstrates a conservative stance with $103.76M in cash against only $7.26M in debt, although the debt-to-equity ratio is listed as N/A due to the negative equity position common in biotech firms. Short-term liquidity appears robust with a current ratio of 2.20, implying the company possesses more than double the current assets necessary to cover its short-term liabilities. Furthermore, the return on equity of -908.3% and return on assets of -26.3% reveal that management is currently deploying capital in ways that result in significant losses, a metric driven by the lack of earnings rather than operational inefficiency in the context of a clinical-stage enterprise.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A and a forward P/E of -13.78, a discrepancy that implies the market is not pricing the stock based on current earnings but rather on future expectations that may eventually turn positive. The price-to-book ratio is recorded at -3.66, which indicates that the market price is negative relative to the book value, a phenomenon often seen in companies with intangible assets or significant accumulated deficits that distort traditional book value calculations. Alternative valuation measures such as the price-to-sales ratio of 18.47 and an EV/EBITDA of 1.59 suggest the stock is priced at a premium relative to its current sales volume, reflecting the high potential value placed on its pipeline despite current profitability challenges. Regarding trading ranges, the 52-week high is $16.52 and the 52-week low is $6.47, meaning the current valuation sits within a wide band of historical volatility without necessarily indicating a specific premium or discount without the current price point provided for a precise percentage calculation. The beta value of -0.02 suggests an extreme inverse correlation to the broader market, indicating that the stock's price movements are driven almost entirely by company-specific factors rather than general market sentiment, leading to highly idiosyncratic volatility.
Growth & Income
The revenue growth year-over-year is an exceptional 742.5%, driven by the inclusion of acquired assets or specific milestone recognitions, while the earnings growth is N/A, indicating that earnings are not growing faster than revenue because the company is not yet profitable. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings to reinvest into its clinical programs rather than distributing cash to shareholders. This reinvestment strategy is essential for a clinical-stage biotechnology firm that must prioritize funding the discovery and development of tumor-activated immuno-oncology therapies over shareholder distributions. Overall, the growth and income profile is characterized by explosive top-line expansion and zero current income distribution, reflecting a capital-intensive business model focused entirely on long-term product development rather than immediate financial returns.